A Phase II Multicenter Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Brief description of study
If you have been diagnosed with any of the following cancers: colon cancer, rectal cancer, pancreatic cancer, liver cancer, small bowel cancer, bile duct cancer, or esophageal cancer; you may qualify to participate in a clinical trial. The main goal of this phase II trial is to evaluate the anti-tumor activity of the investigational drug, ceritinib. This study will determine what good or bad effects the drug, ceritinib may have, and to determine the cancer cell growth (disease progression) in you over the course of a specific time frame.
Clinical Study Identifier: s16-00695
ClinicalTrials.gov Identifier: NCTs16-00695
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
